Frontier Medicines lures Astellas exec to be its CMO

Privately-held US precision medicines company Frontier Medicines Corporation has appointed Dr Andrew Krivoshik as chief medical officer.

Joining the US firm from his post with Japanese drug major Astellas (TYO: 4503), Dr Krivoshik is a preeminent expert in drug development with proven leadership in the process of discovering, designing and delivering precision and oncology medicines to patients.

“We are excited to welcome Dr Krivoshik, a seasoned drug developer and physician, to the Frontier team,” said Chris Varma, Frontier’s co-founder, chairman, and chief executive. “Andy’s appointment comes at a pivotal time as we both prepare FMC-376, our novel dual KRASG12C inhibitor, for the clinic and rapidly progress our pipeline of precision medicines. Dr Krivoshik brings a rich background in oncology and hematology, and has led the development of some of the world’s top medicines. His experience will be instrumental to Frontier’s efforts to bring transformational medicines to patients,” he noted.